Fits Health

Fit And Well, Daily

Breaking News
Sport Nutrition

Google DeepMind speeds up drug discovery with AI tools

By Fern Covington November 21, 2026
Google DeepMind speeds up drug discovery with AI tools - ai drug discovery
Access to the tools is available through the Science plug-in within the Antigravity application.

Google DeepMind has enhanced its Antigravity platform with new AI-driven tools meant to speed up drug discovery workflows. The update introduces an AI agent capable of collecting chemical data, evaluating compound effectiveness, and recommending new molecular structures for laboratory testing.

The capabilities were showcased using two non-small cell lung cancer therapies: crizotinib and lorlatinib. The AI reviewed scientific literature and patent databases, sifting through thousands of compound records to isolate relevant chemical frameworks. Researchers then examined how minor structural adjustments, such as attaching a bond to create a cyclic structure, impacted drug potency.

During testing, the AI determined that ring-shaped molecules exhibited greater rigidity and efficacy. It developed predictive models for potency and proposed additional ring-based compounds, alongside suggested synthesis pathways. The entire process took roughly an hour in the demonstration, a significant reduction from the days required by conventional methods. The company emphasized that any proposed design would still require experimental confirmation.

Access to the tools is available through the Science plug-in within the Antigravity application. To encourage adoption, Google is providing six months of complimentary access to its highest-tier usage for 10,000 researchers, contingent on meeting eligibility criteria.

This development comes amid broader industry shifts. Earlier this year, Isomorphic Labs raised $2.1 billion to expand its AI-focused drug discovery initiatives. Collaborations between Iambic and AbbVie, as well as Owkin and Sanofi, highlight increasing partnerships between AI firms and pharmaceutical companies.

Traditionally, drug discovery depended on iterative trial-and-error testing, with each synthesis and validation cycle lasting weeks or months. Tools like these seek to reduce that timeline by automating data review and generating candidate proposals more efficiently. Still, experimental validation remains critical, as computational predictions must correspond with practical biological outcomes.

The new features represent a broader push to embed AI across the research process, from initial modeling to late-stage development. While the technology accelerates hypothesis testing, its real-world success hinges on how well these predictions convert into functional treatments.

Google DeepMind’s announcement follows reports that its AI systems have previously achieved breakthroughs in protein folding and molecular analysis. The company stated that the Antigravity tools would be refined based on user feedback, with additional features planned for later releases.

Leave a Reply

Your email address will not be published. Required fields are marked *

© 2026 Fits Health. All rights reserved.